Novartis

Fabrikstrasse 2, 4056 Basel
Novartis   link
Lieu: Bâle
Domaine: Pharmacologie
Lié:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Économie - 28.02
Patients & Caregivers Healthcare Professionals Society & ESG - Shareholders approve 23 rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5% 1 yield and approximately 54% payout of free cash flow -   Shareholders confirm Dr. Joerg Reinhardt as Chairman of the Board of Directors as well as all other members who stood for re-election; Ms.
Pharmacologie - Santé - 25.02

Patients & Caregivers Healthcare Professionals Society & ESG - LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust -   Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic coun

Pharmacologie - Santé - 17.02

Patients & Caregivers Healthcare Professionals Society & ESG - Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading phase 1 -   For the more than 20

Pharmacologie - Santé - 31.01

Patients & Caregivers Healthcare Professionals Society & ESG - New Cosentyx (secukinumab) US label to include 300 mg up-titration option is based on Phase III MEASURE 3 study results in ankylosing spondylitis (AS) 1 -   Label update provides clinicians with greater choice for their patients

Pharmacologie - Économie - 29.01

Patients & Caregivers Healthcare Professionals Society & ESG - Full year net sales for c ontinuing operations 1 up 9% (cc2, +6% USD): - Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 mi

Pharmacologie - Santé - 24.02

Patients & Caregivers Healthcare Professionals Society & ESG - Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as annualized relapse rate (ARR) 1 -  

Pharmacologie - Santé - 11.02

Patients & Caregivers Healthcare Professionals Society & ESG FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC) 1 -   Substantial unmet need exists

Pharmacologie - Économie - 31.01

Patients & Caregivers Healthcare Professionals Society & ESG - Successful acquisition of Aspen's Japanese operations and assets reinforces strategic focus on Japan, world's third largest market for generics and off-patent medicines Acquired portfolio complements existing Sandoz portfolio an

Pharmacologie - Santé - 20.01

Patients & Caregivers Healthcare Professionals Society & ESG - Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe 1 -   Mayzent addresses an unmet need for SPMS patie



Offres d'emploi

» Offre d'emploi: Novartis

Dernières offres d'emploi



website preview

Lien

Médecine et sciences de la vie